Resources
Clear thinking on pharma portfolio and project governance.
Short, practical explainers for the decisions pharma leaders, PMOs, and finance teams actually make.
Welcome to the PortiVix resource hub
A quick look at how our editorial team publishes practical guides on pharma portfolio and project governance.
ReadWhat is pharma portfolio governance?
Why R&D-heavy pharma organisations are moving from status packs and email ownership to a governed operating model - and what that actually means day to day.
ReadPTRS, explained for portfolio decisions
Probability of technical and regulatory success is the number every phase-gate turns on. Here is how it fits alongside business, IP, API/supply, and KSM risk.
ReadeNPV vs NPV for pharma portfolios
Two molecules can share the same NPV and be worth very different amounts to your pipeline. Risk-adjusted value is why - and how leaders should use it.
ReadSee your portfolio operating model in PortiVix.
We do not start with a generic demo. We map your portfolio, molecule, project, approval, reporting, and governance workflows first - then show how PortiVix would work for your organisation.